George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
Maybe Als fooked up the US route too so now he's come back cap in hand to the UK, and FDA approval for first line treatment wasn't a shoe in after all. Wouldn't surprise me after fooking up BAMS, the LFT fook up in fooking up the application process as spotted and pointed out to them by members on here ffs, fooking up last AGM by saying chemo warheads are old and outdated so not worth pursuing despite it being our lead fooking pathfinder asset, fooking up by losing key staff at a critical time, fooking up the route to market by saying we need a 1b, oh we dont need a 1b, oh yes we do actually need a 1b but we won't call it that, fooking up the previous placing by not forseeing the interest in Avacta and missing out on millions of £ at 90p or so, fooking up commercials with latest car crash placing by not only letting his mates buy in cheap at 50, but timing it at the stupidest time, and fooking up by appointing a chief business offer in a panic when it should have been sorted 12 months ago.
What a fook up, at least he hasn't had the nerve for a pointless waffly interview with Paul Hill. Roll on June agm. Wouldn't surprise me if its done remote only this year.
I feel better now
Personally I think the FDA were p1ssed off at Als rampy "paradigm shift" bolox with no clinical proof and have now insisted Avacta do it properly, keeping a careful eye on them, hence the flowery language used in recent rns. I bet Tap is livid with the morons running things. Maybe the placing done now because there's gonna be an RNS shortly (ha) to say "We fvcked up, again, things have been delayed", which would have crushed the SP even more and saw a placing at 20p if done before.
I can't see any route on how AS can remain in charge. Imagine him trying to get ava6k on to market, he'd fvck that up and sell at a loss probably.
Just hope we don't end up like COPL with the board helping their mates steal the company from PIs. Wouldn't put it past them now. They now have as little as 18 months to do something positive with the cash generated and get a licence deal that would cover costs of a phase 3 trial, keep the co a going concern and fund the rest of the pipeline, otherwise can see this being a billion pound company come 2026 but with a billion shares in float. They have an uphill battle now, poor sentiment, untrustworthy board, low SP, and angry LTHs, big pharma would love to get the precision platform while paying millions instead of billions.
Yes, I'm still angry
Can you explain what this means, is there a limit on number of shares or amount of shares that can be created when on main market? I tend to only stick with cowboy lifestyle companies like Avacta on AIM so not heard of this before.
Why would you spend millions buying diagnostics businesses, only to look at flogging them at what will be a massive loss.
Why would you arrange a placing in such a car crash manner
Why would you not at least wait until after aacr. Or until new tax year.
Why would you tell shareholders not to worry about funding.
Why is no one serious in our platform, is there something going on what we're not being told about?
Why would you admit to the market that you think we're overvalued.
Can't wait for AGM, time to vote AS out. He's gonna need a bigger venue for all the angry LTH. I gave him benefit of the doubt after the LFT fiasco, but this is just utter incompetence. Maybe hes qualified enough to be a lab assistant. Makes me hope some US firm makes a £3 a share offer as I don't think these have the ability to bring this platform to market. Hell I'd take £2 right now just to put an end to this clusterfook.
As the other post says, now the market knows we're in distress, wouldn't surprise me to see the SP crash below 50 causing terms of placing to change.
Yes Mr India.
This share needs more than "a small punt" from a wannabe day trader who'll just sell as soon as he gets his 20%. How else do you explain the SP? Market "thick as mince"? Yeah, I read that alot on the Avacta board too.
A placing now, before they've announced results of phase 1 and had the data peer reviewed, would show they don't know what they're doing and that they've failed commercially.
Which is why I think it's very unlikely. Why bother appointing Simon Bennett otherwise if you're just going to undermine discussions with a cheap fund faise.
Imo the quiet is because it's in the hands of lawyers, and Al doesn't want to jeopardise on going talks. And we know there is discussions because they said so.
People like Swaz, wyn, thorn, eggy, vikingraider and touk might well be annoying twats, but I gotta say they're all far more accurate than the likes of Myles, RAH and Tom the Bomb have been over the last few years.
Still, makes no difference if SP is 80p or £1.80 right now as I have no intention of selling any until we reach double digits, which I'm pretty confident will happen by 2027
Apparently he serves in consulting/advisory role for AffyImmune Therapeutics, AstraZeneca, Ayala Pharmaceuticals, Bristol-Myers Squibb, Cellestia Biotech, CureVac, Eisai Inc., Elevar Therapeutics, Exelixis, Expert Conncet, Genzyme, InxMed, Kura Oncology, McGivney Global Advisors, Merck & Company Inc., Novartis, CureVac, Prelude Therapeutics, Regeneron, Rgenta, Sanofi, Sun Pharma, the Chemotherapy Foundation, and TRM Oncology.
No doubt soon to be advising them they can all go home now, Avactas cracked it.
Has vlad indicated how many years phase 1 is expected to take to complete along with peer review? Will give a rough idea how long until we require funding for expensive p2 phase.
Prevail have only stumped up a tiny amount of cash compared to other biotechs they've invested in so id expect they'll be contributing further. Whether it'll be again at 6p I've no idea, would be happy to see a couple of million at 4p.
I said a week or two ago based on my experience with Avacta that moving in to clinic won't suddenly supercharge the SP and was jumped on by a few self appointed board mods. Their SP is lower than before they dosed a single patient.
Patience required now. Like with Avacta, maybe the market is waiting to see how things are going to be funded.
Funny how the bipolar mrindia 'sold' just before we flew past 3p having held for so long and now gone quiet.
Guess he's on to the next share to pretend to be a worried investor in
Don't think the move to clinical will be the catalyst people think it will. I think it will rise, but investors will always have one eye on funding
Avacta SP is lower now than before a single patient was enrolled on trial, and still dropping, and they're about to close phase 1a which has gone better than envisaged and move to phase 2, and just 2-3 years from commercialisation. Granted their starting point was a lot higher, but then they're creating a whole platform and managed something no other pharma has.
Jupiter shorted Avacta back in 2022 - an anti cancer company during its preclinical stages and at its most vulnerable- utterly abhorrent. I hope these get f|_|ucking destroyed.
Thing that caught my eye is that he's been operating as a consultant for last 13 years - presumably making a lot of money working with a lot of varied clients all on his own terms and in his own time. Not many people towards the end of their careers move from the comfort of LTD operated consultancy back to permie with a boss and shareholders to answer to, even with ir35 being a threat, unless they're offered an opportunity impossible to turn down.
Which begs the questions what has he seen within Avacta thats made him make the switch. I presume he would have asked what deals are currently in the pipeline, who the prospective partners are and marketable value as well as the data so far during interview process. He could have offered to take the role on a consultancy basis, and probably for more money, negotiate a few contracts and then get back down to the pub for a working lunch, but looks like he's in it for the long haul. Is he looking to make a name for himself negotiating the biggest UK pharma deal ever made?
Ramper rockets are go!